Next Article in Journal
Hibiscus Acid from Hibiscus sabdariffa L. Inhibits Flagellar Motility and Cell Invasion in Salmonella enterica
Next Article in Special Issue
Computational Identification of Druggable Bioactive Compounds from Catharanthus roseus and Avicennia marina against Colorectal Cancer by Targeting Thymidylate Synthase
Previous Article in Journal
The Effect of Salvia hispanica and Nigella sativa Seed on the Volatile Profile and Sensory Parameters Related to Volatile Compounds of Dry Fermented Sausage
Previous Article in Special Issue
Insulin Complexation with Cyclodextrins—A Molecular Modeling Approach
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 3
10.3390/molecules27030653
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Phytochemical Compound Screening to Identify Novel Small Molecules against Dengue Virus: A Docking and Dynamics Study

by
Mst. Sharmin Sultana Shimu
1,†,
Shafi Mahmud
2,†,
Trina Ekwati Tallei
3,
Saad Ahmed Sami
4,
Ahmad Akroman Adam
5,
Uzzal Kumar Acharjee
1,*,
Gobindo Kumar Paul
2,
Talha Bin Emran
6,
Shahriar Zaman
2,
Md. Salah Uddin
2,
Md. Abu Saleh
2,*,
Sultan Alshehri
7,
Mohammed M Ghoneim
8,
Maha Alruwali
8,
Ahmad J. Obaidullah
9,10,
Nabilah Rahman Jui
11,
Junghwan Kim
12 and
Bonglee Kim
13,*
1
Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi 6205, Bangladesh
2
Microbiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi 6205, Bangladesh
3
Department of Biology, Faculty of Mathematics and Natural Science, Sam Ratulangi University, Manado 95115, Indonesia
4
Department of Pharmacy, University of Chittagong, Chittagong 4331, Bangladesh
5
Dentistry Study Program, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia
6
Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh
7
Department of Pharamaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
8
Department of Pharmacy Practice, College of Pharamcy, AlMaarefa University, Ad Diriyah 13713, Saudi Arabia
9
Drug Exploration and Development Chair (DEDC), Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
10
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
11
Department of Biochemistry and Biotechnology, University of Science and Technology, Chittagong 4202, Bangladesh
12
Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea
13
Department of Pathology, College of Korean Medicine, Kyung Hee University, Hoegidong Dongdaemungu, Seoul 05253, Korea
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2022, 27(3), 653; https://doi.org/10.3390/molecules27030653
Submission received: 15 December 2021 / Revised: 10 January 2022 / Accepted: 14 January 2022 / Published: 20 January 2022
(This article belongs to the Special Issue Computational Strategy for Drug Design)
Browse Figures
Versions Notes

Abstract

:
The spread of the Dengue virus over the world, as well as multiple outbreaks of different serotypes, has resulted in a large number of deaths and a medical emergency, as no viable medications to treat Dengue virus patients have yet been found. In this paper, we provide an in silico virtual screening and molecular dynamics-based analysis to uncover efficient Dengue infection inhibitors. Based on a Google search and literature mining, a large phytochemical library was generated and employed as ligand molecules. In this investigation, the protein target NS2B/NS3 from Dengue was employed, and around 27 compounds were evaluated in a docking study. Phellodendroside (−63 kcal/mole), quercimeritrin (−59.5 kcal/mole), and quercetin-7-O-rutinoside (−54.1 kcal/mole) were chosen based on their binding free energy in MM-GBSA. The tested compounds generated numerous interactions at Lys74, Asn152, and Gln167 residues in the active regions of NS2B/NS3, which is needed for the protein’s inhibition. As a result, the stable mode of docked complexes is defined by various descriptors from molecular dynamics simulations, such as RMSD, SASA, Rg, RMSF, and hydrogen bond. The pharmacological properties of the compounds were also investigated, and no toxicity was found in computational ADMET properties calculations. As a result, this computational analysis may aid fellow researchers in developing innovative Dengue virus inhibitors.

1. Introduction

The Dengue virus is spread by the mosquito Aedes aegypti, which is mostly found in tropical and subtropical areas [1]. Currently, 2.5 billion people around the world are at danger of contracting Dengue fever, with hundreds of millions of people suffering from the disease [2]. Climate change, population increase, and deforestation all contribute to the spread of Dengue fever, resulting in recurring outbreaks and more intense transmission of diverse serotypes [3]. The Dengue virus has four different serotypes, and infection with one of them does not confer protection against the other serotypes [4]. As a result, Dengue infections caused by two different serotypes carry the risk of Dengue hemorrhagic fever [5]. Despite the fact that many studies are still ongoing and that a large number of people are affected by Dengue fever on a daily basis, no effective inhibitors have been identified. As a result, a novel technique for the identification of a powerful Dengue inhibitor is required [6,7].
As a result, the Dengue virus is classified as an RNA virus with a single-stranded positive-sense RNA genome of 10.7 kb [8,9,10]. The Dengue virus RNA genome is transcribed as a single polyprotein, and subsequently co- and post-translationally cleaved into three structural proteins (Capsid (C), pre-membrane (prM), envelope (E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [11,12,13]. These structural proteins, on the other hand, mediate the proteolytic processing that is mediated by the endoplasmic reticulum-based host cell signal peptidase [14]. Cleavage occurs in the NS2A/NS2B, NS2B/NS3, NS3/NS4A, and NS4B/NS5 sites by the NS2B/NS3 protease. As a result, this viral protease from Dengue also cleaves the internal side of C, NS2A, NS3, NS4A, and C/prM. As a result, the NS2B/NS3 function as a key viral protease, which is significant for the development of antiviral drugs against the Dengue virus that can interfere with the virus’s functions [15,16].
Multiple efforts are currently underway to find efficient Dengue virus inhibitors and vaccines by targeting various structural and non-structural proteins. As a result, Dengvaxia, a Dengue vaccine, has been studied in two independent phase 3 clinical trials in Latin America and Asia, with efficacy ranging from 31.3 percent to 79 percent, demonstrating diversity in vaccine efficacy across different geographies and serotypes [17,18]. Despite various efforts by experts, there are currently no antiviral medications available on the market for the Dengue virus. Furthermore, Zingiberaceae chalcone compounds have been shown to inhibit the DENV2 protease. Various isolated substances, such as panduratin A and 4-hydroxypanduratin, also have inhibitory activity [19]. Quercetin and agathisflavone [20], dehydronaphthalene [21], benzimidazole [22], thiadiazoloacrylamide [23], and drug designing process [24,25] are some of the powerful compounds that target the NSB2/NS3 from phytochemicals.
Curdlan sulfate [26], rolitetracycline [26], fucoidan [27], balapiravir [28], suramin [29], carnosine [30], policresulen [31], dasatinib [32], duramycin [33], luteolin [34,35], and imatinib [36] are examples of DAA or direct acting antivirals that efficiently interact by targeting NS and structural proteins. DAA, on the other hand, has the ability to target viral proteins and usually has a lower level of toxicity, but it comes with the acknowledged drawback of a higher likelihood of resistance development [37]. Furthermore, numerous DAA candidates for Dengue failed in mice experiments despite showing promise in in vitro assays, and only balapiravir has been studied in human trials among many DAA candidates [38]. Furthermore, due to the lower chance of acquiring resistance, host directed antivirals, or HDAs, have a lot of potential in a broader range, but only a few candidates have made it to the clinical trial stage [39]. Cleavages of florescence energy transfer (FRET), HPLC-based detection, isothermal titration calorimetry, and surface plasmon resonance have also been used to identify various protease inhibitors [37,40,41,42].
We conducted a virtual screening working flow of phytochemicals against the viral protein target of NS2B/NS3 in this investigation. The binding affinity and MM-GBSA techniques aid in the screening of phytochemical libraries and the selection of molecules with the highest binding energy. A molecular dynamics simulation was also carried out to further evaluate the docked complexes’ binding conformations and stability.

2. Results

2.1. Molecular Docking Analysis

For improved energy against viral NS2B/NS3 protease (PDB ID: 2FOM), a total of 27 compounds were chosen, with docking scores ranging from −6.5 kcal/mol to −3.4 kcal/mol. The binding affinity of choerospondin diaplayed (−6.576 kcal/mol) to the target receptor was the highest whereas the control exhibit −5.1 kcal/mol energy. The other compounds displaying top docking scores included nortanshinone (−6.1 kcal/mol), forsythoside A (−6 kcal/mol), luteone (−5.8 kcal/mol), paeonidanin B (−5.6 kcal/mol), phellamuretin (−5.5 kcal/mol), sesamin (−5.3 kcal/mol), asarinin (−5.3 kcal/mol), 6’’-O-acetylliquiritin (−5.2 kcal/mol), quercimeritrin (−5.2 kcal/mol), phellodendroside (−5.1 kcal/mol), hydroxytanshinone (−5.1 kcal/mol), methylophiopogonanone A (−5 kcal/mol), narirutin (−5 kcal/mol), and quercetin-7-O-rutinoside (−5 kcal/mol). Therefore, the XP score was found higher for cherospondin (−5.1 kcal/mol), angustidine (−6 kcal/mol), forsythoside A (−5.8 kcal/mol), luteon (−5.9 kcal/mol), quercimeritrin (−6 kcal/mol), hydroxytanshinone (−5.4 kcal/mol), phellodendroside (−6.1 kcal/mol), quercetin-7-O-rutinoside (−5.9 kcal/mol), phellamuretin (−5.8 kcal/mol), and control (−5.4 kcal/mol), respectively. The majority of the compounds interacted with our target receptor’s Lys74, Leu76, Trp83, Leu85, Asn152, and Ile165 active site residues via hydrogen and hydrophobic contacts. Table 1 and Figure S1 show the docking score and amino acid interactions between the selected drugs and the Dengue virus NS2B/NS3 protease.

2.2. Prime MM-GBSA Simulation

We used Prime MM-GBSA attributes to compute the binding energy of the ligands with the Dengue virus NS2B/NS3 protease to assess the clarity of the molecular docking simulation. The binding free energy of a ligand molecule with a lower negative value suggests that it has better binding abilities. The results showed that most of the ligands’ binding energies imply a strong binding engagement with the target receptor. Phellodendroside (−63 kcal/mole), quercimeritrin (−59.5 kcal/mole), and quercetin-7-O-rutinoside (−54.1 kcal/mole) are the top ligand–receptor complexes, and the control exhibits a higher binding energy of −51.3 Kcal/mole. Table 1 and Figure 1, Figure 2, Figure 3 and Figure 4 show the results of the binding free energies, three compounds (Figure 1, Figure 2 and Figure 3), and a control (Figure 4) with improved amino acid interactions at the active site of the target protein, respectively.

2.3. ADMET Analysis

Pharmacological and toxicity evaluation are critical in assuring the efficacy and safety of lead compounds. The screened compounds were evaluated using the parameters molecular weight, h bond acceptor, h bond donor, CYP2D6 substrate, CYP3A4 substrate, CYP1A2 inhibitor, CYP2C19 inhibitor, CYP2C9 inhibitor, CYP2D6 inhibitor, CYP3A4 inhibitor, AMES toxicity, and oral acute toxicity (Table 2). Phellodendroside, quercimeritrin, and quercetin-7-O-rutinoside had molecular weights of 518.51, 464.38, and 610.52g/mol, respectively. There is no CYP inhibition in any of the drugs. In AMES toxicity and oral rat acute toxicity profile, the chemical displays no toxicity.

2.4. Molecular Dynamics Simulation

To further understand the stability and stiffness of the docked complexes, molecular dynamics simulations were used. The simulated trajectories were used to calculate the root mean square deviations from the C-alpha atoms of the complexes. Figure 5A demonstrates that at the start of the simulations, phellodendroside, quercetin-7-O-rutinoside, and quercimeritin have an upper trend in RMSD, indicating that the complexes were still flexible. The complexes, on the other hand, had established a stable state after 20ns and had maintained their integrity until the simulations’ final images. The quercimeritin displayed a greater RMSD trend and more fluctuations at 40–55 ns periods, indicating the complex’s more flexible character; however, the complexes eventually settled into a stable state. RMSD was less than 2.5 Å for all complexes until the end of the simulations, indicating that the complexes were overall stable.
Furthermore, the solvent accessible surface area (SASA) of the simulated complexes was examined, with a larger trend in SASA indicating the expansion of the protein’s surface area and a lower SASA indicating the complex’s truncated nature. Figure 5B shows that phellodendroside had a larger SASA trend and a higher degree of departures from 60–70 and 80–100 ns compared to other complexes, indicating that when ligand binds to the protein, the surface area expands and the stability decreases. The radius of gyrations from the simulated trajectories was also determined, with the larger Rg indicating a more mobile character of the complexes and the lower Rg indicating a stiffer structure. From 30 ns to the rest of the simulation durations, the complexes of phellodendroside had a greater Rg than the other complexes, indicating that the complexes are more labile (Figure 5C). In simulation trajectories, the other complexes show smaller degrees of divergence.
In determining the stable state of the complexes, the hydrogen bond plays a crucial role. Figure 5D shows that all complexes showed lower degrees of hydrogen bond patterning aberrations. The root mean square fluctuations (RMSF) of the complexes, which determine the flexibility across the amino acid residues, were also calculated. Figure 6 shows that the maximum residues had an RMSF of less than 2.5, indicating that the complexes were overall stable.

3. Discussion

Molecular docking is one of the most widely used methods in computational drug design for predicting the orientation of tiny molecules attached to the binding pocket of an enzyme or receptor [43]. The binding affinities of chosen drugs against Dengue virus NS2B/NS3 protease were investigated using molecular docking simulation in this work. In conjugation with the NS2B cofactor, NS3, a trypsin-like viral protease, is a crucial regulator of viral replication [44]. Potential protease inhibitors derived from Carica papaya leaves interacted with the NS3 protease active site’s Leu149 and conserved substrate-binding residue Asn152. Bioflavonoids extracted from Azadirachta indica, such as rutin, hyperoside, kaempferol-3-O-rutinoside, and epicatechin, interacted with the Asn152 residue of the NS3 protease active site [45]. Lys74, Leu76, Trp83, Leu85, Glu88, Ile165, Ala166, and Asn167 active site residues of the dengue NS2B/NS3 protease were found to be involved in hydrophobic and hydrogen bond formation in a recent study based on antiviral phytochemicals [46]. Similar interactions were also found for a few amino acid residues in the dengue NS2B/NS3 protease active site (Lys74, Asn152, and Gln167) in several experimentally tested synthetic compounds [47]. Three compounds were chosen for this study: quercimeritrin, phellodendroside, and quercetin-7-O-rutinoside, based on their amino acid interactions, docking scores, and binding free energies. Quercimeritrin interacted with the NS3 protease active site residues Lys74, Leu76, Trp83, Leu85, Glu88, Asn152, Asn167, whereas phellodendroside interacted with Trp69, Lys74, Trp83, Trp89, Val146, Val147, Gly148, Ile165. Quercetin-7-O-rutinoside established hydrogen bonds with the NS2B/NS3 protease residues Asp71, Lys74, Trp83, Gly87, Val147, and Ile165. Multiple hydrogen bonds were formed between the control ligand molecules and the target protein at Val72, His51, Arg54, and Phe130, as well as one hydrophobic interaction at Leu128.
Multiple interactions were also observed at Asn152 and Lys74 by benzothiazole derivatives in molecular modeling studies, and their inhibition of replications was validated in vitro and in a cell-based PR assay for distinct Dengue serotypes [48]. Benzimide also generated hydrogen-bond interactions at Asn152, and the hydrophobic side of the benziminazole ring immediately attached to engage with Lys74 and Leu76, which are identical to the interactions of the top three compounds in this study [49]. In recent fragment-based drug design efforts against Dengue virus NS2B/NS3 revealed that Asn167, Leu85, and Glu88 were important in generating non-covalent interactions with the NS2B/NS3 protein [50]. Our screened compounds’ interaction patterns were also shown to be similar for papraine A, robustune, eryvarin, sigmodin, osaji, and laburnetin [51].
Based on the findings of the previous investigations, these amino acid interactions showed that these compounds could be effective as dengue NS2B/NS3 protease inhibitors. Although molecular docking is a reliable method for predicting a small molecule’s binding poses, it still requires additional validation to appropriately rank the ligands’ affinities to the target receptor. We used Prime MM/GBSA analysis to verify the docking experiments, which is a revolutionary QM/MM property for calculating relative binding affinities using the best poses from ligand-receptor interactions [52]. Within the binding site of the Dengue virus NS2B/NS3 protease, phellodendroside has the highest MM-GBSA binding energy of approximately −63 kcal/mole. The binding free energies of quercimeritrin and quercetin-7-O-rutinoside were also acceptable, confirming the results of our docking experiment.
In addition, a molecular dynamics simulation investigation was carried out for further docking conformation validations [53,54,55]. For a better understanding of the docked complexes’ stable nature, numerous characteristics from simulated trajectories were evaluated. The RMSD, RMSF, Rg, hydrogen bond, and SASA define the complexes and show that they are more stable. As a result, the complexes’ pharmacological properties were investigated to assure their safety and toxicity level [56,57,58]. To be used as drug candidates, substances must have particular drug-like qualities and have a low level of toxicity [59,60,61]. In ADMET calculations, the top three compounds show no toxicity profiling and have favorable drug similarity features.
In addition, the MM-GBSA binding free energy following molecular dynamics simulations shows that the complex; quercimeritrin, phellodendroside, and quercetin-7-O-rutinoside exhibited binding free energies of −51.3Kcal/mol, −54.3Kcal/mol, and −52.7Kcal/mol, respectively. The superimpositions of the pre- and post-MD docked structures revealed (Figure 7) that the phellodendroside, quercetin-7-O-rutinoside, and quercimeritrin complexes had RMSD of 1.186, 1.01, and 1.04, respectively, indicating that the docked complexes had less structural deviations during molecular dynamics simulations.
The top three phytochemicals may have the ability to interfere with the operation of Dengue virus NS2B/NS3 protease, according to combinatorial bioinformatics methodologies such as molecular dynamics and molecular dynamics simulations. This work also tabulated fresh phytochemical information, which will aid researchers in using additional targeted viral proteins or signaling molecules. Although the data in this work were generated exclusively through computational methods, they still have to be confirmed in a wet lab setting using several enzymatic assays.

4. Material and Methods

4.1. Ligand Retrieval and Preparation

Based on the literature research, about 2000 phytochemical substances were collected from the Pubchem database [62] (Table S1, Supplementary Materials). The structures were neutralized using Epik 2.2 at pH 7.0 ± 2.0, and the force field OPLS 2005 contained in Maestro, version 10.1 (Schrödinger suite) [63] was used to reduce them. Per ligand, up to 32 stereoisomers were preserved.

4.2. Protein Preparation

The RCSB PDB [64,65] provided three-dimensional crystallographic structures of the proteins utilized in this study: Dengue virus NS2B/NS3 protease (PDB ID: 2FOM) [66]. To prepare and modify crystallographic structures for molecular docking experiments, the Protein Preparation Wizard of Maestro version 10.1 (Schrödinger suite) was used. Hydrogens were added to the heavy atoms, selenomethionines were transformed to methionines, and all waters were removed. Minimization was carried out using the force field OPLS 2005, with the maximum heavy atom RMSD (root mean square deviation) set to 0.30 [67,68].

4.3. Virtual Screening

For virtual screening, the Glide software from the Schrodinger working flow was used, which offers different docking protocols, HTVS (high-throughput virtual screening), standard precision, and SP. The best compounds from the pool were identified using the prior techniques. Every ligand was docked against the receptor using HTVS, which results in a single posture. About half of all plant-derived chemicals were shifted from HTVS to SP, reducing the number of false positives [69,70]. Here, 1-(4-{5-[(piperidin-4-yl)methoxy]-3-[4-(1H-pyrazol-4-yl)phenyl]pyrazin-2-yl}phenyl)methanamine was used a control ligand molecules [71].

4.4. Prime MM-GBSA Simulation

Based on SP score, a total of 27 biological compounds were chosen for MM-GBSA study against Dengue virus NS2B/NS3 protease. The binding energies of the ligands with the Dengue virus NS2B/NS3 protease were calculated using the Prime MM-GBSA (Molecular Mechanics/Generalized Born Surface Area) technique. The prime module of the Schrödinger suite, Maestro version 10.1, was used for this. The MM-GBSA technique combines the OPLSAA molecular mechanics energies (EMM), a surface generalized Born (SGB) model for polar solvation (GSGB), and a non-polar solvation term (GNP) made up of non-polar solvent accessible surface area and van der Waals interactions [72]. Here, the Glide pose viewer file of the best conformation was given as the source in Prime MM-GBSA simulation [73]. The total free energy of binding:
ΔGbind = Gcomplex − (Gprotein + Gligand), where G = EMM + GSGB + GNP

4.5. ADMET Analysis

SwissADME [74], admetSAR [75], and pkCSM [76] were used to calculate the pharmacological and pharmacokinetic parameters of the three compounds. As an entry system, the ligand molecules’ canonical simplified molecular input line entry system (SMILES) was used.

4.6. Molecular Dynamics Simulation

Molecular dynamics simulations of docked complexes were carried out using YASARA dynamics [77] and the AMBER14 force field [78]. Initial cleaning, optimization, and orientation of hydrogen bond networks were performed on docked complexes. In a cubic simulation cell with periodic boundary conditions, the TIP3P water solvation model was used [79]. The simulation cell’s physiological conditions were set at 298K, pH 7.4, and 0.9% NaCl. The particle mesh Ewalds (PME) approach was used to calculate long-range electrostatic interactions with a cutoff radius of 8.0 [80,81,82]. The steepest gradient techniques were used to implement the initial energy minimization procedure using the simulated annealing approach (5000 cycles). The simulation’s time step was set to 2.0 fs [83]. After every 100 ps period, the simulation trajectories were saved. The simulation was extended for 100 ns by using a constant pressure and Berendsen thermostat, and trajectories were used to compute the root mean square deviation (RMSD), root mean square fluctuations (RMSF), solvent accessible surface area (SASA), radius of gyration (Rg), and hydrogen bond [84,85,86,87].

5. Conclusions

To select the effective inhibitors from the compounds, this study used structure-based screening of phytochemicals. As a result, hundreds of phytochemicals have been identified in plants, particularly in Asian species. Based on greater binding affinity and MM-GBSA binding free energy, the top three compounds were chosen: phellodendroside (−63 kcal/mole), quercimeritrin (−59.5 kcal/mole), and quercetin-7-O-rutinoside (−54.1 kcal/mole). As a result, a molecular dynamics analysis was carried out to confirm the structural stability and binding pose. The toxicity and carcinogenicity of the tested molecules shows no possible adverse effect of the compounds. This study relies primarily on computational screening and pipelines; nonetheless, these studies must be confirmed in the wet lab using several enzymatic assays.

Supplementary Materials

The following are available online, Figure S1: 2D representation of the selected compounds against Dengue Virus NS2B/NS3 Protease (PDB: 2FOM). (A) Rutaecarpine, (B) Sesamin, (C) Choerospondin, (D) Evodiamine, (E) Narirutin, (F) Angustidine, (G) Forsythoside A, (H) Luteone, (I) Quercimeritrin, (J) Hydroxytanshinone, (K) Methylophiopogonanone A, (L) Tanshinlactone, (M) Piperitylhonokiol, (N) Sanjoinine B, (O) Sanjoinine D, (P) Scutianine D, (Q) Scutianine C, (R) 6’’-O-Acetylliquiritin, (S) Phellodendroside, (T) Quercetin-7-O-Rutinoside, (U) (S)-Suspensaside, (V) Paeonidanin B, (W) Phellamuretin, (X) Nortanshinone, (Y) Sec-O-Glucosylhamaudol, (Z) Benzoyloxypaeoniflorin, and (AA) Asarinin. Table S1: Selected plants, their compounds and CID of each compound.

Author Contributions

M.S.S.S.: Conception, Data curation, Formal analysis, Investigation, Methodology, Writing; S.M.: Conception, Data curation, Formal analysis, Investigation, Methodology, Writing; T.E.T.: Conception, Data curation, Formal analysis, Investigation; S.A.S.: Conception, Data curation, Formal analysis, Investigation; A.A.A.: Conception, Data curation, Formal analysis, Investigation, Visualisation; U.K.A.: Conception, Investigation, Validation, Supervision; G.K.P.: Conception, Data curation, Formal analysis, Investigation; T.B.E.: Conception, Data curation, Formal analysis, Investigation, Methodology; S.Z.: Conception, Data curation, Formal analysis, Investigation, Validation; M.S.U.: Conception, Data curation, Formal analysis, Investigation, Writing, Editing; M.A.S.: Conception, Project administration, Editing, and Supervision; S.A.: Validation, Conception, Data curation, Formal analysis, Investigation; M.M.G.: Funding, Conception, Data curation, Formal analysis, Investigation; M.A.: Software, Conception, Data curation, Formal analysis, Investigation, Project administration; A.J.O.: Software, Validation, Conception, Data curation, Formal analysis, Investigation; N.R.J.: Software, Conception, Data curation, Formal analysis, Investigation, Funding; J.K.: Data curation, Formal analysis, Writing, Editing, Funding; B.K.: Conception, Data curation, Formal analysis, Investigation, Editing, Funding. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1I1A2066868), the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No.2020R1A5A201941311).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in this article and supplementary material.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are available from the authors.

References

  1. Gubler, D.J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 1998, 11, 480–496. [Google Scholar] [CrossRef] [Green Version]
  2. Leong, A.S.-Y.; Wong, K.T.; Leong, T.Y.-M.; Tan, P.H.; Wannakrairot, P. The pathology of dengue hemorrhagic fever. Semin. Diagn. Pathol. 2007, 24, 227–236. [Google Scholar] [CrossRef] [Green Version]
  3. Bhatt, S.; Gething, P.W.; Brady, O.J.; Messina, J.P.; Farlow, A.W.; Moyes, C.L.; Drake, J.M.; Brownstein, J.S.; Hoen, A.G.; Sankoh, O.; et al. The global distribution and burden of dengue. Nature 2013, 496, 504–507. [Google Scholar] [CrossRef]
  4. Rodenhuis-Zybert, I.; Wilschut, J.; Smit, J.M. Dengue virus life cycle: Viral and host factors modulating infectivity. Cell. Mol. Life Sci. 2010, 67, 2773–2786. [Google Scholar] [CrossRef]
  5. Guzman, M.G.; Alvarez, M.; Halstead, S.B. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: An historical perspective and role of antibody-dependent enhancement of infection. Arch. Virol. 2013, 158, 1445–1459. [Google Scholar] [CrossRef] [PubMed]
  6. Tatem, A.J.; Hay, S.; Rogers, D.J. Global traffic and disease vector dispersal. Proc. Natl. Acad. Sci. USA 2006, 103, 6242–6247. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Pitisuttithum, P.; Bouckenooghe, A. The first licensed dengue vaccine: An important tool for integrated preventive strategies against dengue virus infection. Expert Rev. Vaccines 2016, 15, 795–798. [Google Scholar] [CrossRef] [PubMed]
  8. Frimayanti, N.; Chee, C.F.; Zain, S.M.; Rahman, N.A. Design of New Competitive Dengue Ns2b/Ns3 Protease Inhibitors—A Computational Approach. Int. J. Mol. Sci. 2011, 12, 1089–1100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Chung, K.Y.; Dong, H.; Chao, A.T.; Shi, P.-Y.; Lescar, J.; Lim, S.P. Higher catalytic efficiency of N-7-methylation is responsible for processive N-7 and 2′-O methyltransferase activity in dengue virus. Virology 2010, 402, 52–60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Tomlinson, S.M.; Watowich, S.J. Anthracene-based inhibitors of dengue virus NS2B–NS3 protease. Antivir. Res. 2011, 89, 127–135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Chambers, T.J.; Hahn, C.S.; Galler, R.; Rice, C.M. Flavivirus Genome Organization, Expression, And Replication. Annu. Rev. Microbiol. 1990, 44, 649–688. [Google Scholar] [CrossRef] [PubMed]
  12. Preugschat, F.; Yao, C.W.; Strauss, J.H. In vitro processing of dengue virus type 2 nonstructural proteins NS2A, NS2B, and NS3. J. Virol. 1990, 64, 4364–4374. [Google Scholar] [CrossRef] [Green Version]
  13. Falgout, B.; Pethel, M.; Zhang, Y.M.; Lai, C.J. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 1991, 65, 2467–2475. [Google Scholar] [CrossRef] [Green Version]
  14. Markoff, L. In vitro processing of dengue virus structural proteins: Cleavage of the pre-membrane protein. J. Virol. 1989, 63, 3345–3352. [Google Scholar] [CrossRef] [Green Version]
  15. Takagi, Y.; Matsui, K.; Nobori, H.; Maeda, H.; Sato, A.; Kurosu, T.; Orba, Y.; Sawa, H.; Hattori, K.; Higashino, K.; et al. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity. Bioorganic Med. Chem. Lett. 2017, 27, 3586–3590. [Google Scholar] [CrossRef] [PubMed]
  16. Falgout, B.; Miller, R.H.; Lai, C.J. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: Identification of a domain required for NS2B-NS3 protease activity. J. Virol. 1993, 67, 2034–2042. [Google Scholar] [CrossRef] [Green Version]
  17. Capeding, M.R.; Tran, N.H.; Hadinegoro, S.R.S.; Ismail, H.I.H.M.; Chotpitayasunondh, T.; Chua, M.N.; Luong, C.Q.; Rusmil, K.; Wirawan, D.N.; Nallusamy, R.; et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384, 1358–1365. [Google Scholar] [CrossRef]
  18. Hamdy, R.F. Literature Review. J. Pediatr. Infect. Dis. Soc. 2015, 4, 389–392. [Google Scholar] [CrossRef] [Green Version]
  19. Kiat, T.S.; Pippen, R.; Yusof, R.; Ibrahim, H.; Khalid, N.; Rahman, N.A. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorg. Med. Chem. Lett. 2006, 16, 3337–3340. [Google Scholar] [CrossRef]
  20. De Sousa, L.R.F.; Wu, H.; Nebo, L.; Fernandes, J.B.; das Graças Fernandes da Silva, M.F.; Kiefer, W.; Kanitz, M.; Bodem, J.; Diederich, W.E.; Schirmeister, T.; et al. Flavonoids as noncompetitive inhibitors of Dengue virus NS2B-NS3 protease: Inhibition kinetics and docking studies. Bioorg. Med. Chem. 2015, 23, 466–470. [Google Scholar] [CrossRef]
  21. Viswanathan, U.; Tomlinson, S.M.; Fonner, J.M.; Mock, S.A.; Watowich, S.J. Identification of a Novel Inhibitor of Dengue Virus Protease through Use of a Virtual Screening Drug Discovery Web Portal. J. Chem. Inf. Model. 2014, 54, 2816–2825. [Google Scholar] [CrossRef]
  22. Raut, R.; Beesetti, H.; Tyagi, P.; Khanna, I.; Jain, S.K.; Jeankumar, V.U.; Yogeeswari, P.; Sriram, D.; Swaminathan, S. A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture. Virol. J. 2015, 12, 16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Liu, H.; Wu, R.; Sun, Y.; Ye, Y.; Chen, J.; Luo, X.; Shen, X.; Liu, H. Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease. Bioorganic Med. Chem. 2014, 22, 6344–6352. [Google Scholar] [CrossRef]
  24. Cabarcas-Montalvo, M.; Maldonado-Rojas, W.; Montes-Grajales, D.; Bertel-Sevilla, A.; Wagner-Döbler, I.; Sztajer, H.; Reck, M.; Flechas-Alarcon, M.; Ocazionez, R.; Olivero-Verbel, J. Discovery of antiviral molecules for dengue: In silico search and biological evaluation. Eur. J. Med. Chem. 2016, 110, 87–97. [Google Scholar] [CrossRef]
  25. Kee, L.Y.; Kiat, T.S.; Wahab, H.A.; Yusof, R.; Rahman, N.A. Nonsubstrate Based Inhibitors of Dengue Virus Serine Prote-ase: A Molecular Docking Approach to Study Binding Interactions between Protease and Inhibitors. Asia-Pac. J. Mol. Biol. Biotechnol. 2007, 15, 53–59. [Google Scholar]
  26. Ichiyama, K.; Reddy, S.B.G.; Zhang, L.F.; Chin, W.-X.; Muschin, T.; Heinig, L.; Suzuki, Y.; Nanjundappa, H.; Yoshinaka, Y.; Ryo, A.; et al. Sulfated Polysaccharide, Curdlan Sulfate, Efficiently Prevents Entry/Fusion and Restricts Antibody-Dependent Enhancement of Dengue Virus Infection In Vitro: A Possible Candidate for Clinical Application. PLoS Negl. Trop. Dis. 2013, 7, e2188. [Google Scholar] [CrossRef] [Green Version]
  27. Hidari, K.I.P.J.; Takahashi, N.; Arihara, M.; Nagaoka, M.; Morita, K.; Suzuki, T. Structure and anti-dengue virus activity of sulfated polysaccharide from a marine alga. Biochem. Biophys. Res. Commun. 2008, 376, 91–95. [Google Scholar] [CrossRef]
  28. Chen, Y.-L.; Ghafar, N.A.; Karuna, R.; Fu, Y.; Lim, S.P.; Schul, W.; Gu, F.; Herve, M.; Yokohama, F.; Wang, G.; et al. Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates Balapiravir. J. Virol. 2013, 88, 1740–1747. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Basavannacharya, C.; Vasudevan, S.G. Suramin inhibits helicase activity of NS3 protein of dengue virus in a fluorescence-based high throughput assay format. Biochem. Biophys. Res. Commun. 2014, 453, 539–544. [Google Scholar] [CrossRef] [PubMed]
  30. Rothan, H.A.; Abdulrahman, A.Y.; Khazali, A.S.; Rashid, N.N.; Chong, T.T.; Yusof, R. Carnosine exhibits significant antiviral activity against Dengue and Zika virus. J. Pept. Sci. 2019, 25, e3196. [Google Scholar] [CrossRef] [PubMed]
  31. Wu, D.-W.; Mao, F.; Ye, Y.; Li, J.; Xu, C.-L.; Luo, X.-M.; Chen, J.; Shen, X. Policresulen, a novel NS2B/NS3 protease inhibitor, effectively inhibits the replication of DENV2 virus in BHK-21 cells. Acta Pharmacol. Sin. 2015, 36, 1126–1136. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. De Wispelaere, M.; Lacroix, A.J.; Yang, P.L. The Small Molecules AZD0530 and Dasatinib Inhibit Dengue Virus RNA Replication via Fyn Kinase. J. Virol. 2013, 87, 7367–7381. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Richard, A.S.; Zhang, A.; Park, S.-J.; Farzan, M.; Zong, M.; Choe, H. Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses. Proc. Natl. Acad. Sci. USA 2015, 112, 14682–14687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Peng, M.; Watanabe, S.; Chan, K.W.K.; He, Q.; Zhao, Y.; Zhang, Z.; Lai, X.; Luo, D.; Vasudevan, S.G.; Li, G. Luteolin restricts dengue virus replication through inhibition of the proprotein convertase furin. Antivir. Res. 2017, 143, 176–185. [Google Scholar] [CrossRef]
  35. Adeoye, A.O.; Oso, B.J. Investigative studies on the inhibition of amyloid-like fibrils formation by the extracts of Vernonia amygdalina Del. leaf. Adv. Tradit. Med. 2021, 1–14. [Google Scholar] [CrossRef]
  36. Clark, M.J.; Miduturu, C.; Schmidt, A.G.; Zhu, X.; Pitts, J.D.; Wang, J.; Potisopon, S.; Zhang, J.; Wojciechowski, A.; Chu, J.J.H.; et al. GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chem. Biol. 2016, 23, 443–452. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Boldescu, V.; Behnam, M.A.M.; Vasilakis, N.; Klein, C.D. Broad-spectrum agents for flaviviral infections: Dengue, Zika and beyond. Nat. Rev. Drug Discov. 2017, 16, 565–586. [Google Scholar] [CrossRef] [Green Version]
  38. Radi, M.; Botta, L.; Rivara, M.; Zuliani, V. Drug repurposing approaches to fight Dengue virus infection and related diseases. Front. Biosci. 2018, 23, 997–1019. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Low, J.G.; Gatsinga, R.; Vasudevan, S.G.; Sampath, A. Dengue Antiviral Development: A Continuing Journey. In Advances in Experimental Medicine and Biology; Springer: Singapore, 2018; Volume 1062, pp. 319–332. [Google Scholar]
  40. Leung, D.; Schroder, K.; White, H.; Fang, N.-X.; Stoermer, M.; Abbenante, G.; Martin, J.L.; Young, P.; Fairlie, D. Activity of Recombinant Dengue 2 Virus NS3 Protease in the Presence of a Truncated NS2B Co-factor, Small Peptide Substrates, and Inhibitors. J. Biol. Chem. 2001, 276, 45762–45771. [Google Scholar] [CrossRef] [Green Version]
  41. Yusof, R.; Clum, S.; Wetzel, M.; Murthy, H.M.K.; Padmanabhan, R. Purified NS2B/NS3 Serine Protease of Dengue Virus Type 2 Exhibits Cofactor NS2B Dependence for Cleavage of Substrates with Dibasic Amino Acids in Vitro. J. Biol. Chem. 2000, 275, 9963–9969. [Google Scholar] [CrossRef] [Green Version]
  42. Nitsche, C.; Holloway, S.; Schirmeister, T.; Klein, C. Biochemistry and Medicinal Chemistry of the Dengue Virus Protease. Chem. Rev. 2014, 114, 11348–11381. [Google Scholar] [CrossRef]
  43. Gohlkea, H.; Hendlicha, M.; Klebea, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2000, 295, 337–356. [Google Scholar] [CrossRef] [PubMed]
  44. Melino, S.; Paci, M. Progress for dengue virus diseases: Towards the NS2B-NS3pro inhibition for a therapeutic-based ap-proach. FEBS J. 2007, 274, 2986–3002. [Google Scholar] [CrossRef]
  45. Dwivedi, V.D.; Bharadwaj, S.; Afroz, S.; Khan, N.; Ansari, M.A.; Yadava, U.; Tripathi, R.C.; Tripathi, I.P.; Mishra, S.K.; Kang, S.G. Anti-dengue infectivity evaluation of bioflavonoid from Azadirachta indica by dengue virus serine protease inhibition. J. Biomol. Struct. Dyn. 2021, 39, 1417–1430. [Google Scholar] [CrossRef] [PubMed]
  46. Rahman, M.; Biswas, S.; Islam, K.J.; Paul, A.S.; Mahato, S.K.; Ali, A.; Halim, M.A. Antiviral phytochemicals as potent inhibitors against NS3 protease of dengue virus. Comput. Biol. Med. 2021, 134, 104492. [Google Scholar] [CrossRef] [PubMed]
  47. Bhowmick, S.; Alissa, S.A.; Wabaidur, S.M.; Chikhale, R.; Islam, A. Structure-guided screening of chemical database to identify NS3-NS2B inhibitors for effective therapeutic application in dengue infection. J. Mol. Recognit. 2020, 33, e2838. [Google Scholar] [CrossRef] [PubMed]
  48. Wu, H.; Bock, S.; Snitko, M.; Berger, T.; Weidner, T.; Holloway, S.; Kanitz, M.; Diederich, W.E.; Steuber, H.; Walter, C.; et al. Novel Dengue Virus NS2B/NS3 Protease Inhibitors. Antimicrob. Agents Chemother. 2015, 59, 1100–1109. [Google Scholar] [CrossRef] [Green Version]
  49. Chen, J.; Jiang, H.; Li, F.; Hu, B.; Wang, Y.; Wang, M.; Wang, J.; Cheng, M. Computational insight into dengue virus NS2B-NS3 protease inhibition: A combined ligand- and structure-based approach. Comput. Biol. Chem. 2018, 77, 261–271. [Google Scholar] [CrossRef]
  50. Knehans, T.; Schüller, A.; Doan, D.N.; Nacro, K.; Hill, J.; Güntert, P.; Madhusudhan, M.S.; Weil, T.; Vasudevan, S.G. Structure-guided fragment-based in silico drug design of dengue protease inhibitors. J. Comput. Mol. Des. 2011, 25, 263–274. [Google Scholar] [CrossRef] [PubMed]
  51. Rasool, N.; Ashraf, A.; Waseem, M.; Hussain, W.; Mahmood, S. Computational exploration of antiviral activity of phytochemicals against NS2B/NS3 proteases from dengue virus. Turk. J. Biochem. 2018, 44, 261–277. [Google Scholar] [CrossRef]
  52. Choudhary, M.I.; Shaikh, M.; Tul-Wahab, A.; Ur-Rahman, A. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation. PLoS ONE 2020, 15, e0235030. [Google Scholar] [CrossRef]
  53. Salmaso, V.; Moro, S. Bridging Molecular Docking to Molecular Dynamics in Exploring Ligand-Protein Recognition Process: An Overview. Front. Pharmacol. 2018, 9, 923. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Wahl, J.; Smieško, M. Endocrine Disruption at the Androgen Receptor: Employing Molecular Dynamics and Docking for Improved Virtual Screening and Toxicity Prediction. Int. J. Mol. Sci. 2018, 19, 1784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Ferreira, R.J.; Bonito, C.A.; Cordeiro, M.N.D.S.; Ferreira, M.-J.U.; Dos Santos, D.J.V.A. Structure-function relationships in ABCG2: Insights from molecular dynamics simulations and molecular docking studies. Sci. Rep. 2017, 7, 15534. [Google Scholar] [CrossRef] [Green Version]
  56. Ekowati, J.; Diyah, N.W.; Nofianti, K.A.; Hamid, I.S. Molecular Docking of Ferulic Acid Derivatives on P2Y12 Receptor and their ADMET Prediction. J. Math. Fundam. Sci. 2018, 50, 203–219. [Google Scholar] [CrossRef]
  57. Kar, S.; Leszczynski, J. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opin. Drug Discov. 2020, 15, 1473–1487. [Google Scholar] [CrossRef] [PubMed]
  58. Wu, F.; Zhou, Y.; Li, L.; Shen, X.; Chen, G.; Wang, X.; Liang, X.; Tan, M.; Huang, Z. Computational Approaches in Preclinical Studies on Drug Discovery and Development. Front. Chem. 2020, 8, 8. [Google Scholar] [CrossRef]
  59. Oduselu, G.; O Ajani, O.; Ajamma, Y.U.; Brors, B.; Adebiyi, E. Homology Modelling and Molecular Docking Studies of Selected Substituted Benzo[d]imidazol-1-yl)methyl)benzimidamide Scaffolds on Plasmodium falciparum Adenylosuccinate Lyase Receptor. Bioinform. Biol. Insights 2019, 13, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Lagorce, D.; Douguet, D.; Miteva, M.; Villoutreix, B.O. Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors. Sci. Rep. 2017, 7, srep46277. [Google Scholar] [CrossRef]
  61. Adegbola, P.I.; Semire, B.; Fadahunsi, O.S.; Adegoke, A.E. Molecular docking and ADMET studies of Allium cepa, Azadirachta indica and Xylopia aethiopica isolates as potential anti-viral drugs for Covid-19. VirusDisease 2021, 32, 85–97. [Google Scholar] [CrossRef] [PubMed]
  62. Kim, S.; Thiessen, P.A.; Bolton, E.E.; Chen, J.; Fu, G.; Gindulyte, A.; Han, L.; He, J.; He, S.; Shoemaker, B.A.; et al. PubChem substance and compound databases. Nucleic Acids Res. 2015, 44, D1202–D1213. [Google Scholar] [CrossRef]
  63. Schrödinger Suite; Schrödinger Release 2020-3; Schrödinger LLC: New York, NY, USA, 2020; Available online: https://www.schrodinger.com/products/maestro (accessed on 14 December 2021).
  64. Bourne, P.E.; Weissig, H. The Protein Data Bank. Nucleic Acids Res. J. 2003, 28, 181–198. [Google Scholar] [CrossRef]
  65. Goodsell, D.S.; Zardecki, C.; Di Costanzo, L.; Duarte, J.M.; Hudson, B.P.; Persikova, I.; Segura, J.; Shao, C.; Voigt, M.; Westbrook, J.D.; et al. RCSB Protein Data Bank: Enabling biomedical research and drug discovery. Protein Sci. 2020, 29, 52–65. [Google Scholar] [CrossRef] [Green Version]
  66. Erbel, P.; Schiering, N.; D’Arcy, A.; Renatus, M.; Kroemer, M.; Lim, S.P.; Yin, Z.; Keller, T.; Vasudevan, S.G.; Hommel, U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 2006, 13, 372–373. [Google Scholar] [CrossRef] [PubMed]
  67. Schrödinger Suite; Protein Preparation Wizard, Schrödinger Release 2015-1; LLC Schrödinger Suite: New York, NY, USA, 2015; Available online: https://www.schrodinger.com/science-articles/protein-preparation-wizard (accessed on 14 December 2021).
  68. Schrödinger Suite. Protein Preparation Wizard; Schrödinger Release 2018-1; LLC Schrödinger Suite: New York, NY, USA, 2018. [Google Scholar]
  69. Greenfield, D.A.; Schmidt, H.R.; Skiba, M.A.; Mandler, M.D.; Anderson, J.R.; Sliz, P.; Kruse, A.C. Virtual Screening for Ligand Discovery at the σ1 Receptor. ACS Med. Chem. Lett. 2020, 11, 1555–1561. [Google Scholar] [CrossRef] [PubMed]
  70. Avci, F.G.; Altinisik, F.E.; Karacan, I.; Karagoz, D.S.; Ersahin, S.; Eren, A.; Sayar, N.A.; Ulu, D.V.; Ozkirimli, E.; Akbulut, B.S. Targeting a hidden site on class A beta-lactamases. J. Mol. Graph. Model. 2018, 84, 125–133. [Google Scholar] [CrossRef]
  71. Yao, Y.; Huo, T.; Lin, Y.-L.; Nie, S.; Wu, F.; Hua, Y.; Wu, J.; Kneubehl, A.R.; Vogt, M.B.; Rico-Hesse, R.; et al. Discovery, X-ray Crystallography and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease. J. Am. Chem. Soc. 2019, 141, 6832–6836. [Google Scholar] [CrossRef] [PubMed]
  72. Adasme-Carreño, F.; Muñoz-Gutierrez, C.; Caballero, J.; Alzate-Morales, J.H. Performance of the MM/GBSA scoring using a binding site hydrogen bond network-based frame selection: The protein kinase case. Phys. Chem. Chem. Phys. 2014, 16, 14047–14058. [Google Scholar] [CrossRef] [PubMed]
  73. Ignjatović, M.M.; Caldararu, O.; Dong, G.; Muñoz-Gutierrez, C.; Adasme-Carreño, F.; Ryde, U. Binding-affinity predictions of HSP90 in the D3R Grand Challenge 2015 with docking, MM/GBSA, QM/MM, and free-energy simulations. J. Comput. Mol. Des. 2016, 30, 707–730. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Cheng, F.; Li, W.; Zhou, Y.; Shen, J.; Wu, Z.; Liu, G.; Lee, P.W.; Tang, Y. admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties. J. Chem. Inf. Model. 2012, 52, 3099–3105. [Google Scholar] [CrossRef] [PubMed]
  76. Pires, D.E.V.; Blundell, T.L.; Ascher, D.B. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J. Med. Chem. 2015, 58, 4066–4072. [Google Scholar] [CrossRef] [PubMed]
  77. Land, H.; Humble, M.S. YASARA: A tool to obtain structural guidance in biocatalytic investigations. In Protein Engineering; Springer: Berlin, Germany, 2018; pp. 43–67. [Google Scholar] [CrossRef]
  78. Wang, J.; Wolf, R.M.; Caldwell, J.W.; Kollman, P.A.; Case, D.A. Development and testing of a general amber force field. J. Comput. Chem. 2004, 25, 1157–1174. [Google Scholar] [CrossRef] [PubMed]
  79. Harrach, M.F.; Drossel, B. Structure and dynamics of TIP3P, TIP4P, and TIP5P water near smooth and atomistic walls of different hydroaffinity. J. Chem. Phys. 2014, 140, 174501. [Google Scholar] [CrossRef] [PubMed]
  80. Essmann, U.; Perera, L.; Berkowitz, M.L.; Darden, T.; Lee, H.; Pedersen, L.G. A smooth particle mesh Ewald method. J. Chem. Phys. 1995, 103, 8577–8593. [Google Scholar] [CrossRef] [Green Version]
  81. Harvey, M.; De Fabritiis, G. An Implementation of the Smooth Particle Mesh Ewald Method on GPU Hardware. J. Chem. Theory Comput. 2009, 5, 2371–2377. [Google Scholar] [CrossRef]
  82. Krieger, E.; Nielsen, J.E.; Spronk, C.A.; Vriend, G. Fast empirical pKa prediction by Ewald summation. J. Mol. Graph. Model. 2006, 25, 481–486. [Google Scholar] [CrossRef]
  83. Krieger, E.; Vriend, G. New ways to boost molecular dynamics simulations. J. Comput. Chem. 2015, 36, 996–1007. [Google Scholar] [CrossRef]
  84. Munia, M.; Mahmud, S.; Mohasin, M.; Kibria, K.K. In silico design of an epitope-based vaccine against choline binding protein A of Streptococcus pneumoniae. Inform. Med. Unlocked 2021, 23, 100546. [Google Scholar] [CrossRef]
  85. Islam, S.; Mahmud, S.; Sultana, R.; Dong, W. Identification and in silico molecular modelling study of newly isolated Bacillus subtilis SI-18 strain against S9 protein of Rhizoctonia solani. Arab. J. Chem. 2020, 13, 8600–8612. [Google Scholar] [CrossRef]
  86. Khan, M.A.; Mahmud, S.; Alam, A.S.M.R.U.; Rahman, E.; Ahmed, F.; Rahmatullah, M. Comparative molecular investigation of the potential inhibitors against SARS-CoV-2 main protease: A molecular docking study. J. Biomol. Struct. Dyn. 2020, 39, 6317–6323. [Google Scholar] [CrossRef] [PubMed]
  87. Bappy, S.S.; Sultana, S.; Adhikari, J.; Mahmud, S.; Khan, A.; Kibria, K.M.K.; Rahman, M.; Shibly, A.Z. Extensive immunoinformatics study for the prediction of novel peptide-based epitope vaccine with docking confirmation against envelope protein of Chikungunya virus: A computational biology approach. J. Biomol. Struct. Dyn. 2021, 39, 1139–1154. [Google Scholar] [CrossRef] [PubMed]
Molecules 27 00653 g001 550
Figure 1. Quercimeritrin binding the Dengue virus NS2B/NS3 protease (PDB: 2FOM), (A) 3D representation and (B) 2D representation. Hydrogen bonds are displayed as green ball and stick, hydrophobic bonds (Pi–alkyl/alkyl interactions) are displayed as light pink ball and stick, carbon–hydrogen bonds are displayed as white ball and stick.
Figure 1. Quercimeritrin binding the Dengue virus NS2B/NS3 protease (PDB: 2FOM), (A) 3D representation and (B) 2D representation. Hydrogen bonds are displayed as green ball and stick, hydrophobic bonds (Pi–alkyl/alkyl interactions) are displayed as light pink ball and stick, carbon–hydrogen bonds are displayed as white ball and stick.
Molecules 27 00653 g001
Molecules 27 00653 g002 550
Figure 2. Phellodendroside binding the Dengue virus NS2B/NS3 protease (PDB: 2FOM), (A) 3D representation and (B) 2D representation. Hydrogen bonds are displayed as green ball and stick, hydrophobic bonds (Pi–Pi/Pi–sigma/amide–Pi interactions) are displayed as deep pink ball and stick, hydrophobic bonds (Pi–alkyl/alkyl interactions) are displayed as light pink ball and stick, carbon–hydrogen bonds are displayed as white ball and stick.
Figure 2. Phellodendroside binding the Dengue virus NS2B/NS3 protease (PDB: 2FOM), (A) 3D representation and (B) 2D representation. Hydrogen bonds are displayed as green ball and stick, hydrophobic bonds (Pi–Pi/Pi–sigma/amide–Pi interactions) are displayed as deep pink ball and stick, hydrophobic bonds (Pi–alkyl/alkyl interactions) are displayed as light pink ball and stick, carbon–hydrogen bonds are displayed as white ball and stick.
Molecules 27 00653 g002
Molecules 27 00653 g003 550
Figure 3. Quercetin-7-O-rutinoside binding the Dengue virus NS2B/NS3 protease (PDB: 2FOM), (A) 3D representation and (B) 2D representation. Hydrogen bonds are displayed as green ball and stick, carbon–hydrogen bonds are displayed as white ball and stick.
Figure 3. Quercetin-7-O-rutinoside binding the Dengue virus NS2B/NS3 protease (PDB: 2FOM), (A) 3D representation and (B) 2D representation. Hydrogen bonds are displayed as green ball and stick, carbon–hydrogen bonds are displayed as white ball and stick.
Molecules 27 00653 g003
Molecules 27 00653 g004 550
Figure 4. The control ligands binding interactions with the Dengue virus NS2B/NS3 protease, (A) 3D representation and (B) 2D representation.
Figure 4. The control ligands binding interactions with the Dengue virus NS2B/NS3 protease, (A) 3D representation and (B) 2D representation.
Molecules 27 00653 g004
Molecules 27 00653 g005 550
Figure 5. The molecular dynamics simulations study of the docked complexes: (A) root mean square deviations, (B) solvent accessible surface area, (C) radius of gyration, and (D) hydrogen bond.
Figure 5. The molecular dynamics simulations study of the docked complexes: (A) root mean square deviations, (B) solvent accessible surface area, (C) radius of gyration, and (D) hydrogen bond.
Molecules 27 00653 g005
Molecules 27 00653 g006 550
Figure 6. The root mean square fluctuations of the complexes were analyzed to understand the flexibility across the amino acid residues.
Figure 6. The root mean square fluctuations of the complexes were analyzed to understand the flexibility across the amino acid residues.
Molecules 27 00653 g006
Molecules 27 00653 g007 550
Figure 7. The superimposition of the pre and post-MD docked complexes; (A) phellodendroside, (B) quercetin-7-O-rutinoside, (C) quercimeritrin complexes, here blue indicates the pre-MD docked complexes, and orange indicates post-MD docked complexes.
Figure 7. The superimposition of the pre and post-MD docked complexes; (A) phellodendroside, (B) quercetin-7-O-rutinoside, (C) quercimeritrin complexes, here blue indicates the pre-MD docked complexes, and orange indicates post-MD docked complexes.
Molecules 27 00653 g007
Table
Table 1. The binding energy and interacting residues of the best 27 phytochemicals, the interactions were analyzed in the Discovery Studio and Pymol package.
Table 1. The binding energy and interacting residues of the best 27 phytochemicals, the interactions were analyzed in the Discovery Studio and Pymol package.
Compound NameDocking Score (Kcal/mol)XP Score (Kcal/mol)ΔGbind (kcal/mol)Hydrogen BondInteractionsHydrophobic Bonds (Pi–Alkyl/Alkyl)Hydrophobic Bonds (Pi–Pi/Pi–Sigma/Pi–Cation/Pi–Anion/Pi–Amide)Hydrophobic Bonds (Pi–Sulfur/Carbon–Hydrogen)
Rutaecarpine−4.2−3.7−39.8Trp83Leu76Ile165-
Sesamin−5.3−4−45.1Lys74, Leu149Leu76-Leu149, Ala164
Choerospondin−6.3−5.1−47.9Lys74, Glu88, Leu149, Asn152, Ala164Leu76Trp83, Ile165-
Evodiamine−4.7 −39Leu85Leu76, Trp83, Leu85Glu88Leu85, Gly87, Val146
−3.1
Narirutin−5−3.6−30.7Lys74, Trp83, Leu85, Gly87, Glu88, Asn152--Leu85, Glu86
Angustidine−4.6−6−45.1Trp83, Leu149Leu76, Ala166-Gly87
Forsythoside A−6−5.8−34.6Glu43, Lys74, Glu86, Gly87, Glu88, Val146Val147-Trp83
Luteone−5.8−5.9−51.1Lys74, Leu85, Asn152, Asn167-Trp83, Ile165Val147
Quercimeritrin−5.2−6−59.5Lys74, Trp83, Leu85, Glu88, Asn152, Asn167Lys74, Leu76-Trp83, Leu85
Hydroxytanshinone−5.1−5.4−49.6Trp83, Gly87, Leu149Leu76, Ala164Ile165Asn152
Methylophiopogonanone A−5−5.1−49.1Trp83, Asn152, Ala164Leu76Ile165Gly148, Ile165
Tanshinlactone−4.6−3.5−40.2Trp83Leu76, Ala164-Glu88, Gly148
Asarinin−5.3−4.2−35.9Lys74, Leu149, Asn167Lys74, Leu76-Trp83, Gly148, Ala164, Ile165
Piperitylhonokiol−4.6−4.7−52.5Leu149, Ala164, Ile165Trp69, Lys74, Leu76Lys74, Trp83, Ile165-
Sanjoinine B−4.3−4.7−48.3Glu88, Asn167Trp83, Ala166-Ile165, Ala166
Sanjoinine D−3.7−5−48.4Lys74, Glu88Trp83, Ala166-Glu88
Scutianine D−3.4−5.1−44.4Lys74, Asn167Trp83Lys74, Trp83Trp83, Ile165, Ala166
Scutianine C−4.1−4.6−42.9Lys74, Asn167Ala166Glu88, Lys90Ala166
6’’-O-Acetylliquiritin−5.2−5.4−52.2Lys74, Glu88, Asn152Lys74, Leu76Lys74, Trp83, Ile165Glu88, Gly148
Phellodendroside−5.1−6.1−63Lys74, Trp89, Val146, Val147, Ile165Trp69Lys74, Trp83Gly148, Ile165
Quercetin-7-O-Rutinoside−5−5.9−54.1Asp71, Lys74, Trp83, Gly87, Val147, Ile165--Trp69, Gly82
(S)-Suspensaside−4.7−3.5−28.2Lys74, Trp83, Gly87, Glu88, Asn167--Trp69, Leu85, Glu86, Glu88, Val147, Gly148
Paeonidanin B−5.6−5.3−47.1Lys74, Leu85, Gly87, Asn152, Ala164, Asn167Lys74, Leu76-Leu85, Gly87, Gly148
Phellamuretin−5.5−5.8−42.9Lys74, Trp89, Lys90, Asn167Ala166Glu88Trp83
Nortanshinone−6.1−5.3−44.1Trp83, Leu149, Asn167Leu76, Ala164Ile165Leu85
Sec-O-Glucosylhamaudol−4.4−4.6−45.7Trp83, Leu85, Leu149Leu76, Ala164Ile165Trp83, Leu85, Gly148
Benzoyloxypaeoniflorin−4.9−5.5−37.8Lys74, Trp83, Gly87, Asn152Lys74, Leu76, Ala166Ile165-
Control−5.1−5.4−51.3Phe130, Val72Arg54, His51Leu128--
Table
Table 2. The pharmacological and toxicity profiling of the screened compounds from SwissADME, ADMETSAR and PKCSM tools.
Table 2. The pharmacological and toxicity profiling of the screened compounds from SwissADME, ADMETSAR and PKCSM tools.
ParameterPhellodendrosideQuercimeritrinQuercetin-7-O-Rutinoside
Molecular weight518.51g/mol464.38g/mol610.52g/mol
H bond acceptor111216
H bond donor6810
CYP2D6 substrateNoNoNo
CYP3A4 substrateNoNoNo
CYP1A2 inhibitorNoNoNo
CYP2C19 inhibitorNoNoNo
CYP2C9 inhibitorNoNoNo
CYP2D6 inhibitorNoNoNo
CYP3A4 inhibitorNoNoNo
AMES toxicityNoNoNo
Oral rat acute toxicity (LD50)2.957 (mol/kg)2.20 (mol/kg)2.53 (mol/kg)
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Shimu, M.S.S.; Mahmud, S.; Tallei, T.E.; Sami, S.A.; Adam, A.A.; Acharjee, U.K.; Paul, G.K.; Emran, T.B.; Zaman, S.; Uddin, M.S.; et al. Phytochemical Compound Screening to Identify Novel Small Molecules against Dengue Virus: A Docking and Dynamics Study. Molecules 2022, 27, 653. https://doi.org/10.3390/molecules27030653

AMA Style

Shimu MSS, Mahmud S, Tallei TE, Sami SA, Adam AA, Acharjee UK, Paul GK, Emran TB, Zaman S, Uddin MS, et al. Phytochemical Compound Screening to Identify Novel Small Molecules against Dengue Virus: A Docking and Dynamics Study. Molecules. 2022; 27(3):653. https://doi.org/10.3390/molecules27030653

Chicago/Turabian Style

Shimu, Mst. Sharmin Sultana, Shafi Mahmud, Trina Ekwati Tallei, Saad Ahmed Sami, Ahmad Akroman Adam, Uzzal Kumar Acharjee, Gobindo Kumar Paul, Talha Bin Emran, Shahriar Zaman, Md. Salah Uddin, and et al. 2022. "Phytochemical Compound Screening to Identify Novel Small Molecules against Dengue Virus: A Docking and Dynamics Study" Molecules 27, no. 3: 653. https://doi.org/10.3390/molecules27030653

Article Metrics

Back to TopTop